** Leerink Partners says digital healthcare platform GoodRx Holdings' shares are significantly undervalued when accounting for co's profit growth
** Market focus after co reported Q3 earnings has been on revenue growth in prescription marketplace, which is linked with retail store closures and ongoing negotiations with pharmacy benefit managers, says brokerage
** "However, there was almost no focus on the continued pacing of EBITDA growth, which has consistently outpaced expectations so far in FY24 and which is expected to remain steady even with potential market-driven revenue softness," says Leerink
** Contracts with Cigna's Express Scripts, CVS' Caremark and others will contribute to co's FY25 earnings, brokerage says
** Brokerage says GDRX is trading at a discount compared with stocks in NASDAQ 100 index
** As of last close, stock has fallen 36.7% YTD vs ~23% rise in
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Comments